Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor
- 1 August 2001
- journal article
- research article
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 36 (8), 1177-1181
- https://doi.org/10.1053/jpsu.2001.25747
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJournal of Clinical Investigation, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumorJournal of Pediatric Surgery, 2000
- Camptothecins: a review of their development and schedules of administrationEuropean Journal Of Cancer, 1998
- Combined effects of angiostatin and ionizing radiation in antitumour therapyNature, 1998
- Topotecan in Pediatric Patients With Recurrent and Progressive Solid TumorsJournal of Pediatric Hematology/Oncology, 1998
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997
- Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agentsInternational Journal of Cancer, 1994
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agentsBioEssays, 1991
- Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in VivoScience, 1990